Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Veerle Kersemans

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Targeting the Tumour: Cell Penetrating Peptides for Molecular Imaging and RadiotherapyVeerle Kersemans, Bart Cornelissen
Current Pharmaceutical Design|September 11, 2008
Cell penetrating peptides for in vivo molecular imaging applicationsVeerle Kersemans, Ken Kersemans, Bart Cornelissen
Nuclear Medicine and Biology|February 7, 2006
Influence of sedation and data acquisition method on tracer uptake in animal models: [123I]-2-iodo-L-phenylalanine in pentobarbital-sedated tumor-bearing athymic miceVeerle Kersemans, Bart De Spiegeleer, John Mertens, et al.
Nuclear Medicine and Biology|August 6, 2008
The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin)Bart Cornelissen, Kristin McLarty, Veerle Kersemans, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 5, 2009
111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1Bart Cornelissen, Veerle Kersemans, Kristin McLarty, et al.
Laboratory Animals|February 17, 2018
Refinement of in vivo optical imaging: Development of a real-time respiration monitoring systemAna L Gomes, Stuart Gilchrist, Veerle Kersemans, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 2021
A Model System to Explore the Detection Limits of Antibody-Based Immuno-SPECT Imaging of Exclusively Intranuclear EpitopesMathew Veal, Gemma Dias, Veerle Kersemans, et al.
European Radiology|March 30, 2021
The presence of contrast agent increases organ radiation dose in contrast-enhanced CTMahta Mazloumi, Gert Van Gompel, Veerle Kersemans, et al.
Nuclear Medicine and Biology|December 27, 2007
Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injectionBart Cornelissen, Kristin McLarty, Veerle Kersemans, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 16, 2008
Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequencesVeerle Kersemans, Bart Cornelissen, Mark D Minden, et al.
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Targeting the Tumour: Cell Penetrating Peptides for Molecular Imaging and RadiotherapyVeerle Kersemans, Bart Cornelissen
Current Pharmaceutical Design|September 11, 2008
Cell penetrating peptides for in vivo molecular imaging applicationsVeerle Kersemans, Ken Kersemans, Bart Cornelissen
Nuclear Medicine and Biology|February 7, 2006
Influence of sedation and data acquisition method on tracer uptake in animal models: [123I]-2-iodo-L-phenylalanine in pentobarbital-sedated tumor-bearing athymic miceVeerle Kersemans, Bart De Spiegeleer, John Mertens, et al.
Nuclear Medicine and Biology|August 6, 2008
The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin)Bart Cornelissen, Kristin McLarty, Veerle Kersemans, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 5, 2009
111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1Bart Cornelissen, Veerle Kersemans, Kristin McLarty, et al.
Laboratory Animals|February 17, 2018
Refinement of in vivo optical imaging: Development of a real-time respiration monitoring systemAna L Gomes, Stuart Gilchrist, Veerle Kersemans, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 2021
A Model System to Explore the Detection Limits of Antibody-Based Immuno-SPECT Imaging of Exclusively Intranuclear EpitopesMathew Veal, Gemma Dias, Veerle Kersemans, et al.
European Radiology|March 30, 2021
The presence of contrast agent increases organ radiation dose in contrast-enhanced CTMahta Mazloumi, Gert Van Gompel, Veerle Kersemans, et al.
Nuclear Medicine and Biology|December 27, 2007
Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injectionBart Cornelissen, Kristin McLarty, Veerle Kersemans, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 16, 2008
Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequencesVeerle Kersemans, Bart Cornelissen, Mark D Minden, et al.
Pageof 9